Summary: In this presentation, our Expert discusses efforts underway at Catalent to accelerate the path to clinic for iPSC-based therapies.

Summary: Scientists are leading a well-funded drive to adapt technology for solid tumors while making the whole process much more economical for patients and payers.

Summary: At Catalent, we implement innovative manufacturing and fill & finish methodologies to accelerate the path to commercial for MSCs and other allogeneic modalities.

Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.

Summary: Experts discuss a breadth of analytical methodologies, fill & finish approaches and manufacturing designs to accelerate CAR-T therapies to commercial readiness phase in this on-demand webinar.

Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.

Summary: In this interview, Catalent expert Judith Jones discusses the challenges associated with advancing a repositioned drug and how to overcome them to achieve strategic success.

Summary: This roundtable is a must-watch for early and late-stage cell therapy innovator companies who are considering a manufacturing partnership.

Summary: In this webinar, experts discuss new cell line development methodologies and how the use of novel technologies can enable simplified process intensification for cell culture harvest and downstream processes.

Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.